The Clinical Significance of HER2+ Breast Cancer and Opportunities for Improved Outcomes
ADCs in HR+ Advanced/Metastatic BC
By
Stanford Medicine
FEATURING
Milana Dolezal
By
Stanford Medicine
FEATURING
Milana Dolezal
Check out related topics by Dr. Dolezal:
1) HR+ mBC: CDK4/6i Progression Management
2) HR+ Advanced/Metastatic BC Treatment Options: Refining Endocrine Sensitivity
1) HR+ mBC: CDK4/6i Progression Management
2) HR+ Advanced/Metastatic BC Treatment Options: Refining Endocrine Sensitivity
Login to view comments.
Click here to Login